The FDA has granted authorization for 20 Zyn nicotine pouch products to be marketed with a claim that they pose a lower risk of certain health conditions compared to cigarettes. Specifically, Zyn can now state that "using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis." This decision is a significant win for Philip Morris International, Zyn's parent company (via Swedish Match, which Philip Morris acquired in a $16 billion deal), as it allows them to provide adult smokers with information about the relative risks of their products. FDA scientists supported this marketing claim, citing "the totality of the evidence."
The FDA's review determined that these Zyn products contain substantially lower amounts of harmful constituents than cigarettes and most smokeless tobacco products, leading to a lower risk of cancer and other serious health conditions. Additionally, evidence suggests that a significant proportion of adults who use cigarettes or smokeless tobacco completely switched to Zyn pouches. Bret Koplow, acting director of the FDA's Center for Tobacco Products, stated that this decision ensures adult users have clear, science-based information to make informed choices. This marks the first time the FDA has authorized the marketing of nicotine pouches with a modified risk claim, viewing them as having real harm-reduction value.
Despite the perceived harm-reduction benefits for adult smokers, concerns remain about the potential appeal of Zyn pouches to young people. While the FDA acknowledges these concerns, it found that youth use remains low, with the 2024 National Youth Tobacco Survey reporting 1.8% of middle and high school students currently using nicotine pouches. The FDA has imposed stringent marketing restrictions to prevent youth exposure, including measures to target advertising to adults aged 21 and older and avoid content appealing to youth. The authorized products include flavors like ZYN Chill, Cinnamon, Citrus, Coffee, Cool Mint, Menthol, Peppermint, Smooth, Spearmint, and Wintergreen, each in 3mg and 6mg nicotine strengths.
However, the FDA's authorization does not mean these products are safe or "FDA approved." The agency emphasizes there is no safe tobacco product and that non-tobacco users should not start. The FDA will continue to monitor the market and could suspend or withdraw authorization if youth initiation significantly increases. This decision underscores the agency's dual approach of promoting harm reduction for adult smokers while attempting to mitigate risks for adolescents.
